Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Docetaxel/Gemcitabine Is Active Against Metastatic Disease
October 4th, 2001
Combination chemotherapy with monthly docetaxel (Taxotere) and weekly gemcitabine (Gemzar) is a highly active regimen in patients with metastatic breast cancer who have received prior chemotherapy. Results from this 39-patient, Phase II clinical trial showed a response rate of 79%, with two complete responses and 29 partial responses. Twenty-five of these patients remained responsive for more than six months. The median survival for the entire study population is 24.5 months, with no significant difference between the 30 patients who received prior chemotherapy in the adjuvant setting only, and the nine patients with prior chemotherapy for...
Source: Women's Health Weekly (2001-10-04)
|
